|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For 114 cases with breast cancer and 280 controls with benign breast disease, NAT2 genotype was determined using allele-specific PCR amplification to detect slow acetylator mutations.
|
10753193 |
2000 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of NAT2 slow acetylator genotype, and CYP1A2, GSTA1, and GSTM3 variants were associated with an average 3-5 fold increased risk.
|
25719551 |
2015 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When comparing the extreme genotype combinations of the NAT2 rapid acetylator, higher mEH activity genotype to the NAT2 slow acetylator, and very low mEH activity genotype, the corresponding ORs at 0 and 80 pack-years were 0.30 (95% CI, 0.14-0.62) and 2.19 (95% CI, 1.26-3.81), respectively.
|
11815396 |
2002 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to women with the slow acetylator genotype, the main effects odds ratios (OR) for NAT2 were 1.4 for the intermediate acetylator genotype (95% confidence limits (CL) 0.7, 2.7) and 3.6 for the homozygous rapid acetylator genotype (95% CL 1.1, 11.4) (P for trend = 0.05).
|
15225898 |
2004 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the ADRs emerged earlier in the AS cases carrying both NAT1 and NAT2 slow acetylator genotypes.
|
25413361 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hepatic dysfunction in NAT2 slow acetylator recipient patients during the 6-month period after SMX administration was not observed.
|
22106207 |
2012 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore.
|
10469638 |
1999 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the genotypic distribution of variants of slow-acetylator genotypes (NAT2*6/7, NAT2*5/7, and NAT2*5/6) was also not significantly different in ATDIH.
|
31245212 |
2019 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results of the meta-analyses did not also provide conclusive evidence for an overall association of NAT2 slow acetylator genotypes to PD.
|
16571112 |
2006 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that patients with slow-acetylator genotypes (NAT2 5/7, 6/7) and GSTM1 allele of GST enzyme were at higher risk of ATT-induced hepatotoxicity.
|
24188272 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type), homozygous null GSTM1 genotype and MnSOD mutant C allele.
|
24593909 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Slow acetylator phenotype in the rabbit results from deletion of the N-acetyltransferase 2 (NAT2) gene.
|
28536864 |
2017 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 genotypes (*4, *12A, *5A, *5B, *5C, *6, *7) were determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in 84 breast cancer patients and 103 healthy controls, and 50% and 56.3%, respectively, were found to be slow acetylator genotypes.
|
15162844 |
2004 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow acetylator genotype appears to be a significant risk factor for moderate and severe drug- induced liver injury.
|
24888881 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, we failed to show any difference in the level of urinary mutagenicity between slow-acetylator and fast-acetylator NAT2 genotypes among smokers (n = 17) or non-smokers (n = 35).
|
8200080 |
1994 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2*5C, NAT2*5A and NAT2*7B gene variants with a slow acetylator pheno-type were most frequently associated with Dukes stage C.
|
17205146 |
2006 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that having a NAT2 slow acetylator genotype is a significant risk factor for BC, particularly in smokers and older individuals.
|
15725609 |
2005 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SASP is known to be mainly metabolized by N-acetyltransferase 2 (NAT2), and acetylation phenotypes (rapid, intermediate and slow acetylator) correlate with NAT2* genotypes.
|
12786839 |
2003 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether the pharmacokinetics (PK) of RGB and AWD21-360 are altered in subjects with Gilbert's syndrome (GS) and/or with frequent N-acetyltransferase 2 (NAT2) slow acetylator (SA) polymorphisms.
|
16402080 |
2006 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This is mainly due to the high percentage of slow acetylator genotypes (SA) in patients compared with controls (60.0 versus 38.9%; P < 0.02) with a distinct preponderance in subjects with minimal/mild endometriosis (69.4%, P < 0.005) where there is a significantly elevated frequency of slow allele S1 (NAT2*5) (P = 0.05).
|
10381818 |
1999 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report here a statistically significant correlation between the NAT2*5C/NAT2*6A slow acetylator genotype and the risk for developing prostate cancer (OR 2.91; 95 % CI 1.43-5.94; p = 0.003) when compared with the rapid phenotype.
|
24816842 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Individuals homozygous for the NAT2*5 allele, which is the most frequent slow-acetylator (SA) allele and shows the lowest acetylator activity, were at a significantly decreased frequency among the cirrhotic patients compared with controls (9% versus 16%; P = 0.042).
|
10232877 |
1999 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, NAT2 gene polymorphism(s) with slow acetylator phenotype is generally associated with the risk of development of ALL in children.
|
25804798 |
2015 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to identify polymorphisms of genes encoding metabolic enzymes NAT2 and GSTM1 in tuberculosis patients in Latvia and to estimate the frequency of NAT2 slow acetylator and GSTM1 null genotypes.
|
27236516 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, NAT2*5A slow acetylator genotype was found to be significantly higher in patients with cervical cancer.
|
19823052 |
2009 |